Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: gene-encoded antibody vaccines - SmartPharm Therapeutics/Sorrento Therapeutics

Drug Profile

Research programme: gene-encoded antibody vaccines - SmartPharm Therapeutics/Sorrento Therapeutics

Alternative Names: Gene MAbs SARs-Cov-2

Latest Information Update: 01 Apr 2020

At a glance

  • Originator SmartPharm Therapeutics; Sorrento Therapeutics
  • Class DNA vaccines; Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 23 Mar 2020 SmartPharm Therapeutics and Sorrento Therapeutics agree to co-develop gene-encoded antibody vaccines for COVID-2019 infections (Prevention)
  • 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in USA (IM)
  • 23 Mar 2020 Sorrento Therapeutics and SmartPharm Therapeutics announces intention to subimit IND application for COVID-2019 infections (Prevention)

Development Overview

Introduction

Prophylactic vaccines comprised of genes that encode antibodies against SARS-CoV-2 antigens are being co-developed by SmartPharm Therapeutics and Sorrento Therapeutics for prevention of COVID-2019 infection. The lead vaccine candidate will be developed by combining the monoclonal antibody platform (G-MABTM library) of Sorrento and non-viral nanoparticle gene delivery platform or Gene MAb™ of SmartPharm. Gene Mab™ platform combines a novel DNA plasmid with long duration of expression and a safe, effective delivery system to be used in standard hypodermic injection. Several monoclonal antibody candidates from the G-MABTM library will be identified that neutralise the viral antigens. The Gene MAb™ platform will then incorporate the selective antibodies to be encoded by gene which will further cause production of protective antibody against the virus directly in the muscle of an individual. Early stage research is ongoing in the US.

Company Agreements

In March 2020, Sorrento Therapeutics and SmartPharm Therapeutics entered into research and development collaboration to develop a gene-encoded antibody or antibodies vaccine for prevention of COVID-2019 infection. The collaboration will utilize monoclonal antibodies against SARS-CoV-2 virus discovered and/or generated by Sorrento that will be encoded into a gene for delivery utilizing SmartPharm’s non-viral nanoparticle platform. Under the collaboration, Sorrento and SmartPharm will develop a gene-encoded antibody or antibodies that can be administered as a prophylaxis against SARS-CoV-2 infection. The collaboration may include candidate development as well as filing of an IND application. Financial details were not disclosed. [1]

Drug Properties & Chemical Synopsis

  • Route of administration IM
  • Formulation Injection
  • Class DNA vaccines, Monoclonal antibodies, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA IM / Injection SmartPharm Therapeutics, Sorrento Therapeutics 23 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
SmartPharm Therapeutics Originator USA
Sorrento Therapeutics Originator USA
SmartPharm Therapeutics Owner USA
Sorrento Therapeutics Owner USA

Development History

Event Date Update Type Comment
23 Mar 2020 Licensing Status SmartPharm Therapeutics and Sorrento Therapeutics agree to co-develop gene-encoded antibody vaccines for COVID-2019 infections (Prevention) [1] Updated 01 Apr 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in USA (IM) [1] Updated 01 Apr 2020
23 Mar 2020 Regulatory Status Sorrento Therapeutics and SmartPharm Therapeutics announces intention to subimit IND application for COVID-2019 infections (Prevention) [1] Updated 01 Apr 2020

References

  1. SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19.

    Media Release
Back to top